NEW YORK, Feb. 17 (GenomeWeb News) - Atugen has extended by one year its non-exclusive target validation and license agreement with Altana Pharma, the company said yesterday.

The extended deal, originally signed in 2001, calls for Atugen to continue validating potential targets supplied by Altana. The agreement provides a license to Altana's gene-silencing and oligonucleotide-delivery technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.